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Calcium alginate (CA) wafer dressings were prepared by lyophilization of hydrogels to 
deliver ciprofloxacin (CIP) directly to the wound site of infected diabetic foot ulcers (DFUs). 
The dressings were physically characterized by scanning electron microscopy (SEM), texture 
analysis (for mechanical and in-vitro adhesion properties), X-ray diffraction (XRD), Fourier 
transform infrared spectroscopy (FTIR). Further, functional properties essential for wound 
healing i.e. porosity, in-vitro swelling index, water absorption (Aw), equilibrium water 
content (EWC), water vapor transmission rate (WVTR), evaporative water loss (EWL), 
moisture content, in vitro drug release and kinetics, antimicrobial activity and cell viability 
(MTT assay) were investigated. The wafers were soft, of uniform texture and thickness and 
pliable in nature. Wafers showed ideal wound dressing characteristics in terms of fluid 
handling properties due to high porosity (SEM). XRD confirmed crystalline nature of the 
dressings and FTIR showed hydrogen bond formation between CA and CIP. The dressings 
showed initial fast release followed by sustained drug release which can inhibit and prevent 
re-infection caused by both Gram-positive and Gram-negative bacteria. The dressings also 
showed biocompatibility (> 85% cell viability over 72 h) with human adult keratinocytes. 
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Chronic wounds arise from tissue injuries or disruption to anatomical structures that heal 
beyond 12 weeks [1]. They are associated with predisposing factors that might disturb the 
balance between wound bioburden and the patient’s immune system or hinder the wound 
healing cycle [2]. The incidence of chronic wounds including diabetic foot, leg, pressure, 
venous and arterial ulcers as well as trauma, has increased significantly in recent years due to 
obesity, aging, high alcohol consumption, smoking, stress, poor nutrition, diabetic mellitus, 
ischemia, venous stasis disease, and high blood pressure [3].  
Diabetic foot ulcers (DFUs) are one of the most common causes of morbidity and high 
risk of lower extremity amputation in diabetic patients [4]. Worldwide, an estimated 15% of 
diabetic patients are affected by DFUs in their lifetime and this has a high cost burden for 
national health providers [5]. For example in England alone, DFUs and associated 
amputations cost taxpayers approximately £972 million to £1.13 billion  in 2014-15 which is 
equivalent to 0.72-0.83% of the entire budget of the National Health Service  [6]. Diabetic 
patients are susceptible to infections of foot ulcers due to peripheral neuropathy and 
peripheral vascular disease resulting in poor circulation and weakened neutrophil function 
[7]. The foot ulcerations are therefore prone to colonization by various pathogenic organisms 
including Staphylococcus aureus, Streptococcus group B, Enterococcus, Clostridium 
perfringens, Enterobacteriaceae, Pseudomonas and Stenotrophomonas maltophilia. 
Staphylococcus aureus is the most common bacteria in DFUs and about 50% of isolates were 
methicillin-resistant S. aureus (MRSA) [8,9]. High microbial load and the presence of drug 
resistant bacteria retard the healing process of DFUs, which increases the rate of amputation 
and mortality [10].  
There are many therapies for DFUs with wound dressings being one of them [11]. 
Current dressings such as hydrogels, hydrocolloids and films available for treating DFUs are 
generally ineffective and no single dressing can fulfil all the requirements for effective 
treatment of DFUs [12]. These dressings struggle to effectively heal highly exuding wounds 
such as DFUs and venous leg ulcers (VLUs) because of inability to absorb and high amount of 
exudates. On the other hand foam, gauze, bandage, sponge and fiber mats are associated with 
pain and patient discomfort during removal. These dressings can also cause dermatitis due to 
adherence to the wound which leads to wound debridement and thereby delaying wound 
healing process [12-15]. Moreover, bioactive dressings such as collagen, hyaluronic acid and 
elastin are expensive. In addition, most of the antibiotic agents used in DFUs are administered 
via the IV route which is inconvenient and leads to non-compliance [16–20]. Furthermore, due 
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to poor circulation at the extremities of diabetic patients, systemic antibiotic treatment is largely 
ineffective and direct delivery to the wound site is required. Antibiotics are sometimes 
incorporated into semi solid formulations (creams, gels and ointments) that are applied directly 
to the wounds to prevent or control infections. However, these dressings have major limitations 
due to their inability to maintain effective drug concentration for a prolonged period at the 
moist wound surface because of short residence time. These semi solid formulations absorb 
fluid rapidly and therefore, become mobile due to loss of rheological properties [12].  
 Lyophilized wafers have been reported as one of the most advanced dressings as drug 
delivery systems to wounds [21–23]. Due to their highly porous nature, wafers can absorb 
large amounts of heavy exudate whilst maintaining a moist environment without damaging 
newly formed tissue that improves wound healing [23]. Generally, chronic ulcers such as 
DFUs produce significant amounts of such exudate which can form slough and such 
collection of exudate under a dressing can cause maceration of surrounding healthy skin and 
also be a conducive environment for infection. The porosity of the wafers also allows gaseous 
(water vapor) exchange which enables evaporation of wound exudates through the polymeric 
matrix to the surrounding environment, thus preventing fluid accumulation under the dressing 
and subsequently reducing the risk of skin maceration and also controlling infections. It has 
been reported that wafers have excellent physicochemical properties in terms of swelling, 
diffusion, wound adhesion, drug stability and drug loading capacity [21,23–26]. Furthermore, 
wafers can be loaded with multiple drugs simultaneously, which imparts multifunctional 
effects [23] and are a compatible delivery system to carry both insoluble and soluble 
antimicrobial drugs which imparts better antimicrobial activity [22]. Wafers can be easily 
applied to the wounds because of its soft, uniform texture and pliable nature. When wafers 
are applied to the wound site, they absorb wound fluids and are transformed into a gel which 
provides moist environment and facilitating pain free removal of the dressings unlike foam or 
gauze, thereby increasing patient compliance [27]. Moreover, the controlled or sustained 
release of antibiotics from wafers may overcome the problem of uncontrolled release of drugs 
from the traditional dressings such as creams and ointments [26, 28]. In addition, medicated 
lyophilized wafers can reduce the cost burden for routine chronic wound healing, because of 
relatively low manufacturing costs [29] compared to other modern dressings such as tissue 
engineered skin substitutes. 
Ciprofloxacin (CIP), a second-generation fluoroquinolone derivative, has been shown to 
be highly effective against both Gram positive and Gram negative bacteria both of which are 
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commonly found in infected wounds. Because of its low minimum inhibitory concentration 
(MIC), it has become a promising drug to incorporate into polymeric dressings for the 
potential treatment of chronic wounds [30-37]. Antibiotics loaded dressings have great 
advantages of avoiding systemic side effects; interference with wound healing and drug 
resistance [38]. Serious adverse effects of systemically administered CIP has been reported 
[39] which creates the need to develop CIP dressings for local application as an alternative 
way for healing of DFUs.    
Calcium alginate (CA), a calcium salt of alginic acid, is extracted from brown seaweed 
and is made up of alternating sequences of β-(1-4) D-mannuronic acid (M-blocks) and α-(1-
4) L-guluronic acid (G-blocks). The proportional distribution of the blocks depends on the 
origin and the part of the seaweed used with the mannuronic and guluronic acid residues 
adopting different conformational structures [40]. It has been found by conformational 
analysis that the di-equatorial mannuronic acid residues in M-block exhibit flexible flat 
ribbon-like chain conformation whilst the di-axially linked guluronic acid residues in G-block 
show rigid structures [41]. Calcium alginate has been widely used in highly exuding wounds 
such as DFUs and pressure and leg ulcers due to its hemostatic properties. It exchanges 
calcium ions with sodium ions present in the blood (wound exudate) and this stimulates 
growth factors including platelet-derived growth factors and cytokines which play a vital role 
in cell recruitment and extracellular matrix deposition [42]. It has been reported as 
biocompatible, bioadhesive, has high water absorption capacity, potential carrier for control 
drug release and non-toxic to cells [43,44]. In vitro wound healing capacity testing of calcium 
alginate based nano fiber bandage in rat model confirmed it as an excellent dressing material 
[45]. Various commercially available silver incorporated calcium alginate based dressings 
have been indicated for DFUs including Algisite Ag®, Sorbalgon Ag®, Gentell Calcium 
Alginate Ag®, and Suprasorb A + Ag Calcium Alginate® [2,46]. However, silver-impregnated 
dressings have been reported to be cytotoxic to keratinocytes and fibroblasts, and delay 
wound healing in animal wound models [47–49]. A Cochrane review of silver based 
dressings concluded that silver dressings do not improve healing of DFUs [50]. Therefore, 
antibiotic loaded dressings can be an alternative way of healing DFUs.  
  This study therefore aims to formulate and characterize medicated advanced dressings 
in the form of lyophilized wafers to deliver therapeutically relevant doses of a broad-
spectrum antibiotic (CIP) directly to the wound site of infected DFUs. The formulated wafers 
were physically characterized by scanning electron microscopy (SEM), X-ray diffraction 
(XRD), Fourier transform infrared spectroscopy (FTIR) and texture analysis (for mechanical 
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hardness and in-vitro adhesion). The dressings were further functionally characterized for 
fluid handling properties by in-vitro swelling studies, moisture content, equilibrium water 
content (EWC), water absorption (Aw), water vapor transmission rate (WVTR), porosity and 
evaporative water loss. In vitro antimicrobial and cell viability studies were performed to test 
the antimicrobial activity and biocompatibility of the wafers respectively. Further, the fluid 
(exudate) handling and biological properties including antimicrobial and cell viability studies 
of the dressings were compared with a commercial silver incorporated CA based 
antimicrobial dressing, Algisite Ag®.  
   
2. Materials and methods 
2.1. Materials 
Calcium alginate (mannuronic acid: guluronic acid ratio 59:41) [CA, (lot number: 
BCBM8132V)], Ciprofloxacin [CIP, (lot number: LRAA6508)], Mueller hinton broth [MH, 
(lot number: BCBR1543V)], tris(hydroxymethyl)aminomethane (lot number: SLBH9329V), 
Dulbecco’s phosphate buffered saline [D-PBS, (lot number: RNBD8494)], trypsin-EDTA 
solution (lot number: SLBM8412V) and fetal bovine serum [FBS, (lot number: 045M3318)] 
were purchased from Sigma-Aldrich (Gillingham, UK). Agar [agar no. 3, technical, (lot 
number: 1334018)], sodium carbonate (lot number: 1546575), sodium chloride (lot number: 
1560652), bovine serum albumin [BSA, (lot number: 1158022)], hydrochloric acid [HCl, (lot 
number: 1480980)], ethanol (batch number: 0933421) and dimethyl sulfoxide [DMSO, (batch 
number: 0890132)] were ordered from Fisher Scientific (Loughborough, UK). Escherichia 
coli (ATCC 25922), Staphylococcus aureus (ATCC 29213) and Pseudomonas aeruginosa 
(ATCC 27853) were obtained from the microbiology lab of the University of Greenwich, 
UK. Adult human primary epidermal keratinocytes (PCS-200-011, ATCC), dermal cell basal 
medium (PCS-200-030, ATCC) and keratinocytes growth kit (PCS-200-040, ATCC) were 
purchased from LGC standards (Middlesex, UK). Methylthiazolyldiphenyl-tetrazolium 
bromide [MTT, (lot number: 1721505)] and trypan blue stain, 0.4% (lot number: 1696154) 




2.2. Preparation of polymer gels 
The blank (BLK) polymeric gels comprising of CA (0.5 - 2% w/w) were prepared by 
adding the polymer powder in tiny amounts into the vortex of a vigorously stirred 0.014 M 
sodium carbonate solution at 50ºC to avoid lump formation. In the case of drug loaded (DL) 
gels, stock solution of CIP was initially prepared at a concentration of 20 mg/ml in 0.1 N 
hydrochloric (HCl). The stock solution was further diluted with 0.014 M sodium carbonate to 
achieve working stock solution at a concentration of 1 mg/ml. Different volumes of the 
working stock of CIP were added to the BLK gels (1% w/w) to achieve drug concentration of 
0.0001-0.0400% w/v in the gel. 
  
2.3. Preparation of lyophilized wafers 
To obtain wafers, 1 g each of the above formulated gels were poured into 24 well plate 
(diameter 15.6 mm) (Corning® Costar® cell culture plates; Sigma-Aldrich) and freeze-dried 
using a Virtis Advantage XL 70 freeze dryer (Biopharma Process System, Winchester, UK) 
in automatic mode. A previously reported lyophilisation cycle was adapted to prepare wafers 
[23]. In brief, the samples were cooled to -5ºC from room temperature for 1 h, and further 
frozen at -50ºC for 8 h (at 200 mTorr). The frozen samples were then primary dried to -25ºC 
(at 50 mTorr) in a sequence of thermal ramps for 24 h, followed by secondary drying at 20ºC 
(at 10 mTorr) for 7 h. 
 
2.4. Scanning electron microscopy (SEM) 
 SEM was used to analyze the surface morphology of the wafers using a Hitachi SU 
8030 (Hitachi High-Technologies, Germany) scanning electron microscope at low 
accelerating voltage (1.0 kV). The wafers were cut into small pieces, and attached to 
aluminium stubs (15 mm diameter), with the help of double-sided adhesive carbon tape (Agar 
Scientific G3357N). After that, wafers were carbon coated before visualization in the 
microscope. The images of BLK and DL wafers were captured at working distances of 18.4 
mm and 8.3 mm respectively at a magnification of x200 using i-scan 2000 software. 
 
2.5 Texture analysis 
2.5.1. Mechanical hardness 
The hardness (resistance to compressive deformation and ease of recovery) of the 
wafers was investigated by using a TA HD Texture analyzer (Stable Microsystem Ltd., 
Surrey, UK) fitted with a 5 kg load cell and Texture Exponent 32 software program to plot 
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and display data. The average thickness (5-6 mm) of the wafers measured by a digital Vernier 
caliper electronic micrometer gauge (one in the middle and four edges) was entered into the 
software before compression. The instrument was set to compression mode and height of the 
6 mm diameter (p/6) cylindrical stainless steel probe calibrated prior to compression. Three 
different wafers of each formulation (n = 3) were compressed by the probe at three different 
places, on both sides of the wafers using a trigger force of 0.001 N, to a depth of 2 mm, at a 
speed of 1 mm/sec, with a 10 mm return distance [21]. The BLK and DL wafers were 
evaluated to determine the effect of increasing drug content on flexibility to select optimum 
drug loading.  
 
2.5.2. In-vitro adhesion studies 
 In-vitro adhesion of the wafers was investigated using the same texture analyzer and 
software program mentioned above (section 2.5.1). In this test, a 35 mm diameter (p/35) 
cylindrical stainless steel probe was attached to the wafers using double-sided adhesive tape. 
To represent chronic wound surface, 500 µl of simulated wound fluid (SWF) containing 
either 2% (w/w) BSA or 5% (w/w) BSA was spread over set gelatin (6.67% w/w) gel. The 
wafer fitted with the probe was lowered until it made contact with the surface of the gelatin 
gel. The texture analyzer was set to run in tensile mode; followed by 60 s contact time with 
an applied force of 1 N and detached at a pre-test and test speed of 0.5 mm/s and post-test 
speed of 1 mm/s, 0.05 N trigger force and 10 mm return distance. The maximum force 
required to separate wafers from the surface of gelatin gel, the area under the curve of force 
versus distance and the total distance (in mm) travelled by wafers till complete separation 
were recorded to represent stickiness (peak adhesive force), total work of adhesion (WOA) 
and cohesiveness respectively. Each formulation was tested in triplicate (n = 3). 
 
2.6. X-ray diffraction (XRD) 
XRD was used to investigate the physical form (amorphous or crystalline) of the pure 
drug, polymer, BLK and DL wafers. The wafers were compressed with a glass slide to cover 
the round tiles of the holder and tightly attached to the sample cells with the help of 
transparent plastic cling film. The experiment was performed using a D8 Advance X-ray 
diffractometer (Bruker, Germany) in transmission mode. The instrument was set at a voltage 
and current of 40 kV and 40 mA, respectively with a primary solar slit of 4o and a secondary 
solar slit of 2.5º whereas the exit slit was 0.6 mm. Lynx Eye silicon strip position sensitive 
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detector was set with an opening of 3º and the Lynx Iris was set at 6.5 mm. The samples were 
scanned between 2 theta scale of 10-50º at a rotation speed of 15 rpm. The step size was 0.02º 
and counting time was 0.1s per step. 
 
2.7 Fluid (exudate) handling properties 
2.7.1 Porosity 
The porosity of wafers and commercial product, fiber mat (Algisite Ag®) was determined 
by the solvent displacement method as previously described [51]. The geometrical 
dimensions (thickness and diameter) of samples were measured by a digital Vernier caliper 
electronic micrometer gauge and total pore volume (V0) was calculated. After that, samples 
were weighed (W0) before immersing in 10 ml of ethanol for 3 h to reach saturation. Ethanol 
displaced the void space of wafers. Finally, the samples were carefully removed from the 
solvent, blotted with tissue paper to remove excess solvent and immediately weighed (W1) to 
avoid loss of ethanol because of its volatile nature. The porosity of the dressings was 
calculated from equation 1. 
Porosity (%) = (W1-W0)/(ρethV0) x 100         (1) 
ρeth : density of ethanol = 0.789 g/cm3 
 
2.7.2 Water absorption, equilibrium water content and swelling index 
Water absorption (Aw) and equilibrium water content (EWC) tests were performed to 
investigate the maximum water uptake and water holding capacities respectively of the 
dressings. In addition, swelling studies were undertaken to investigate the rate of water 
uptake capacity of formulated BLK and CIP loaded wafers compared with a commercial fiber 
mat, Algisite Ag® (Smith & Nephew, UK). The Aw, EWC and swelling tests of all samples 
were investigated in simulated wound fluid (SWF) containing 2% (w/w) bovine serum 
albumin (BSA), 0.02 M calcium chloride, 0.4 M sodium chloride, 0.08 M tris 
(hydroxymethyl) aminomethane in deionized water at a pH of 7.5. For Aw and EWC studies, 
the samples were incubated in 10 ml of SWF at 37ºC continuously for 24 h. In the case of 
swelling test, the samples were dipped into the same amount of SWF at room temperature 
and the changes in weight of swollen samples were recorded every 15 min up to 1 h and then 
every hour up to 5 h.  Before weighing, the samples were blotted carefully with tissue paper 
to remove excess fluid on the surface. The effect of drug concentration on the above 
properties was determined and the experiments were performed in triplicate (n = 3) for each 
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sample. Percentage of Aw, EWC and swelling index (Is) were calculated using equations 2, 3 









𝑥 100       (3) 
Where Ws and Wi are the swollen weight and the initial weight before immersed into SWF 
respectively. 
 
              𝐼𝑠 (%) =
𝑊𝑠𝑡−𝑊𝑑
𝑊𝑑
 𝑥 100                              (4) 
Where Wd is the dry weight of samples before hydration and Wst is the swollen weight of 
samples at different time of hydration.  
 
2.7.3 Water vapor transmission rate 
Using 90-second epoxy glue, the dressings were mounted on the mouth of a 
cylindrical plastic tube (15 mm diameter) containing 4 ml water with 8 mm air gap between 
the samples and water surface. The whole setup was placed in an air-circulated oven at 37°C 




𝑥106 g/m2 day-1      (5) 
 Where A is the area of the mouth of the plastic tube (πr2), Wi and Wt are the weight of the 
whole setup before and after placing into oven respectively. 
 
  2.7.4 Evaporative water loss 
The samples were immersed in SWF and kept in an oven at 37°C for 24 h after which 
the samples were taken out, and dried in the oven at 37°C for 24 h the weight of the samples 
was recorded at regular time intervals. Evaporative water loss was calculated according to the 
formula in equation 6: 
Water loss (%) = Wt/W0 x 100     (6) 





2.7.5 Moisture content 
The residual moisture content of wafers was determined by thermogravimetric 
analysis (TGA) using a Q5000-IR TGA instrument (TA Instruments, Crawley, UK). About 
1.0 - 1.5mg of sample was accurately weighed, loaded and analyzed with dynamic heating 
from room temperature (∼25ºC) to 300ºC at a heating rate of 10ºC/min under inert nitrogen 
(N2) gas at a flow rate of 50 mL/min. The percentage water content was calculated at 100ºC 
using TA Instruments Universal Analysis 2000 software program. 
 
2.8 In-vitro drug dissolution and release profiles 
The total content of CIP within the wafers was investigated before performing drug 
dissolution and release studies. This was done by hydrating the whole wafer in 10 ml of 
HPLC grade purified water at 37ºC with stirring and left overnight to dissolve completely. 
The concentration of CIP in water was determined by HPLC and used to calculate the total 
amount of drug in water representing total drug content (assay) within the wafers.  
Calibration samples were prepared in triplicate in the concentration range from 1 to 100 
μg/ml to plot standard curve (y = 189.35x; R2 = 0.9993) for CIP and used to determine drug 
loading efficiency (%) of the selected formulations used for drug dissolution studies to 
calculate the percent drug released at each time point.   
In vitro drug dissolution studies were performed by a diffusion cell (developed in-
house at the University of Greenwich) containing SWF (pH 7.5) as dissolution medium but 
with no BSA to avoid blocking of the HPLC column. The diffusion cell was designed with a 
wire mesh on which the wafers were placed. The dissolution medium was poured just up to 
the wire mesh so that the lower surface of the wafers was always just touching the dissolution 
medium. The wafers (CA-50 μg, CA-100 μg and CA-250 μg) containing CIP were placed on 
the wire mesh and the whole assembly placed in a water bath maintained at a temperature of 
37ºC with constant stirring (600 rpm). At predetermined time intervals, 1 ml aliquots of 
dissolution medium were withdrawn and analyzed by HPLC, and also replaced with same 
amount of fresh warm medium (37ºC) to keep a constant volume throughout the experiment. 
The dilution due to replacing fresh medium was considered while calculating the percentage 
drug release at each time point. The concentration of CIP released from the wafers was 
determined by applying the calibration curve and percentage drug release plotted against 
time. Triplicate determinations (n = 3) were made for each wafer selected. The kinetics of 
CIP release from the wafers were also determined by finding the best fit of the % release 
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against time data to Higuchi, Korsmeyer-Peppas, zero order and first order equations (see 
supplementary data). 
 
2.9 HPLC analysis 
The HPLC analysis was carried with an Agilent 1200 series HPLC (Agilent 
Technologies, UK ) equipped with quaternary pump, degasser, auto sampler, and Agilent 
Chemstation® software package for running the instrument, data acquisition and data 
analysis. The analyte was separated at ambient temperature using a C18 analytical column. 
The UV detector was set at 280 nm. A two-solvent gradient elution was performed, solvent A 
2% aqueous acetic acid solution and solvent B acetonitrile in the ratio of 70: 30. The flow 
rate was set at 1 ml/min and injection volume at 20 μl. 
 
2.10 In-vitro antimicrobial studies 
Initially, minimum inhibitory concentration (MIC) of pure CIP and drug loaded (DL) 
wafers were determined by broth dilution method (see supplementary data). Further, 
antimicrobial activity of CIP loaded wafers was evaluated against E. coli, S. aureus and P. 
aeruginosa by turbidimetric and Kirby-Bauer disc diffusion methods. 
 
2.10.1 Turbidimetric method   
 In this method, 10 ml of bacterial suspension (106 CFU/ml) was transferred into sterile 
test tubes each containing wafers obtained from gel with different concentrations of drug 
(0.0001-0.040% w/v). One of the tubes was left without sample and used as control. The 
tubes were incubated in an orbital shaking incubator at 37ºC, and absorbance at 625 nm was 
measured at different time intervals (3, 6, 12 and 24 h) after treatment with each formulation. 
The experiment was carried out in triplicate (n = 3) against each organism (E. coli, S. aureus 
and P. aeruginosa).  
 
2.10.2. Kirby-Bauer disk diffusion method 
 Bacterial inocula were prepared from 3-4 separate colonies of the tested organisms 
using a sterile inoculating loop. The colonies were suspended in 3 ml of MH growth medium 
and incubated overnight at 37ºC. After overnight incubation, the turbidity of the bacterial 
suspension was adjusted to a 0.5 McFarland standard (~108 CFU/ml) by diluting with the 
medium. Each suspension was further diluted to 106 CFU/ml (1 in 100) in a sterile tube. A 
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sterile swab was immersed into the tube and streaked on the surface of the entire MH plate 
three times with clockwise rotation. Circular dressings (diameter, 14-15 mm) were placed in 
the center of colonized agar plates and incubated at 37ºC for 24 h, after which zone of 
inhibition (ZOI) in mm was measured using a digital Vernier caliper. 
 
2.11 MTT (cell viability) assay 
MTT assay on adult human primary epidermal keratinocytes (PCS-200-011, ATCC) 
was performed to evaluate the cytotoxicity of the dressings. The cells were cultured and 
maintained according to the ATCC recommended protocol (see supplementary data). Prior to 
testing, the dressings were sterilized with UV radiation overnight in a flow cabinet (NU-437-
300E, NUAIRE). The sterilized samples were then immersed in 2.5 ml of complete growth 
medium and placed in the incubator (Heracell 150i CO2 incubator, Thermo Scientific) at 
37ºC in 5% (v/ v) CO2 for 24 h. The extracts were collected through filtration using 0.2 μm 
filter. The concentration of the cells was optimized for the MTT assay (see supplementary 
data) and the cells were seeded into 96-well microtiter plates at optimum density (10000 
cells/well). The plates were incubated at 37ºC in 5% (v/ v) CO2 for 5 h to allow cells 
adherence. After that, media was removed and 100 μl of each sample extract was placed in 
triplicate into the wells. The plates were left in the incubator at 37 ºC for up to 72 h. After 
each time point (24, 48 and 72 h), 10 µl of MTT reagent was added to each well including 
blank (medium only). The plates were returned to the incubator for 4 h or more until a purple 
precipitate was clearly visible under the inverted microscope (AE2000, Motic). The media 
was then removed and 100 µl of DMSO was added to all wells including controls. The plates 
were returned to the incubator for 30 min and the absorbance recorded at 492 nm by a 
microtiter plate reader (Multiskan FC, Thermo scientific) equipped with SkanIt for Multiskan 
FC 3.1 software (Thermo scientific). Every experiment was carried out in triplicates and 
repeated three times. The percentage of viable cells was calculated using equation 12. 
Cell viability (%) =  
At−Ab
Ac−Ab
∗ 100      (7) 
Where At, Ab and Ac are the absorbance of tested samples, blank (medium only) and 
negative control (untreated cells) respectively.  
Additionally, the effect of sample extracts on the cells morphology and adherence was 
recorded microscopically by FLoid® Cell Imaging Station. In this study, the untreated 
cells and Triton-X-100 (0.01% w/v) treated cells were used as negative (100% viable) and 
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positive controls respectively. Algisite Ag was chosen as a representative standard 
commercial sample for the MTT assay. 
 
2.12 Statistical analysis 
 Statistical methods such as t-test and ANOVA test were performed by Excel to 
compare experimental values between BLK, DL wafers and Algisite Ag® and p values lower 
than 0.05 were considered significant. 
  
3 Results and discussion 
3.1. Formulation development  
 CA gels were prepared by the exchange of calcium ions with the monovalent sodium 
ions [43]. Among the different concentrations of CA gels prepared, 1% w/w was optimum in 
terms of ease of handling, viscous flow and pouring from the container when compared to 
0.5%, 1.5% and 2 % w/w. Fig. 1 shows the digital images of CA based wafers prepared by 
freeze-drying different gel concentrations (% w/w). After freeze-drying all wafers (1-2% w/w 
gels) appeared to be of uniform texture and thickness except wafer prepared from 0.5 % w/w 
gel. Wafers prepared from 0.5% w/w gel did not retain uniform structure because of low 
viscosity of the gel and subsequently low polymer network density. Subsequently.  
lyophilization of less viscous gel promoted premature ice crystallization during freezing and 
sublimation phases which resulted in flaky wafers.  
 
3.2. Scanning electron microscopy (SEM) 
 SEM investigation showed that the BLK wafers were highly porous in morphology 
with large, uniform and circular shaped pores surrounded by a network of polymeric strands 
as shown in Fig. 2. It is reported that gels made from high α-L-guluronic acid alginates 
exhibit the highest porosity [52]. However, incorporation of CIP changed the uniformity of 
the pores in wafers. Increasing amount of CIP resulted in denser cores due to possible 
crosslinking between the drug and polymer during the freeze-drying process. In addition, Fig. 
S1 shows SEM investigation of the both parts of the wafers. The bottom part of the wafer 
appears more porous in morphology than the top part. Such changes in surface characteristics 
has impact on other physicochemical properties such as hardness, swelling, adhesion, EWC, 
water absorption and WVTR [23,53] as discussed below. 




3.3. Texture analysis 
3.3.1. Mechanical hardness 
 The wafers (n = 3) were compressed at three different positions on the top and bottom 
sides to investigate the hardness (resistance to compressive deformation), and internal 
polymer and drug distribution. Hardness of all formulated wafers was tested to select 
optimum gel concentration for drug loading. Wafers prepared from 1% w/w gels showed 
excellent resistance to compression whereas wafers prepared from 1.5% and 2% w/w gels 
appeared very hard and brittle. On the other hand, wafers obtained from 0.5% w/w gel 
appeared to be very soft and flaky in nature which made them very difficult to handle. 
Therefore, the CIP was loaded into 1% w/w gels to obtain DL wafers. 
 Fig. 3 demonstrates the differences in hardness between the top and bottom sides of 
the wafers. The hardness of the top part of the wafers appeared higher than the lower part. 
This could be due to the higher polymer density on the upper part of the wafers than the 
bottom part. This is possible because in the shelf type freeze dryer used, the condenser is 
present in the lower part of the machine and freezing starts from bottom of the gel upwards. 
The higher polymer density leads to a more compact structure on the top surface of the wafer, 
which causes higher resistance to probe penetration. The difference in hardness between the 
sides of the wafers could also be attributed to differences in porosity [25]. As porosity 
increases, there is less force required to reach the required depth of penetration. Therefore, 
the lower surface of the wafers will be an ideal application site for applying to the wound bed 
as it will quickly absorb wound fluid due to higher porosity. Further, lower hardness will 
reduce the likelihood of damaging sensitive newly formed skin cells on a healing wound. 
However, to maintain hardness consistency of the wafers from container to container on a 
commercial scale, the containers must be flat bottom, with a wider diameter so that the gel 
and final wafer height (thickness) after freezing is not too big. Further, same amount of free 
flowing gel need to be poured in each well of the container. This way, the heat distribution 
within the frozen gel during primary drying will be more uniform between the top and bottom 
sides. This will yield thinner flat sheets similar to foam dressings and help produce consistent 
thickness and polymer density and subsequently will give consistent hardness. The advantage 
of wafer delivery dressing is that it can be produced in different sizes and shapes depending 
on the casting container and it can be delivered to the patients to suit the specific application 
area.    
The BLK wafers showed significantly (p = 0.0001) higher hardness than the DL 
wafers (Fig. 3) and the hardness of the drug incorporated wafers decreased gradually with 
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increasing drug content. This could be explained by the fact that after loading drug, the 
availability of free polymer was reduced throughout the matrix, therefore the rigidity of 
polymeric matrix decreased and these results support the SEM observation (Fig. 2) below. In 
addition, the disturbance in porosity of DL wafers also resulted in a reduction of the hardness 
that might affect other physicochemical properties such as swelling, mucoadhesion, EWC, 
WVTR and drug release.  
 
3.3.2. In-vitro adhesion studies 
 Stickiness, work of adhesion and cohesiveness are associated with the bond formation 
between the polymeric matrix and gelatin gel during the contact period.  
Usually chronic wounds such as DFU contain highly viscous exudates [54], therefore in this 
study two different concentrations of BSA (2% w/w and 5% w/w) were used to represent thin 
and viscous wound exudate respectively. CA-BLK wafers showed similar stickiness (1.82 ± 
0.06 N and 1.54 ± 0.47 N) in the presence of light SWF (2% w/w BSA) and viscous SWF 
(5% w/w BSA) respectively. DL wafers showed stickiness values around 0.55-0.26 N in the 
presence of both thin SWF (2% w/w BSA) and thick SWF (5% w/w BSA). It can be observed 
in Fig. 4 that the CA-BLK wafer showed higher stickiness and WOA values than the DL 
dressings in both types of exudates. This could be due to the fact that incorporation of the 
drug into the wafers resulted in poor contact between the polymer chains and hence reduced 
adhesive properties. Stickiness also depends on the pore size distribution of the polymeric 
matrix. SEM images (Fig. 2) illustrated the disturbance in pore size distribution of DL wafers 
and also poorer hydration capacity possibly resulting in reduction in the stickiness.  
 
3.4. X-ray diffraction (XRD) 
 Fig. 5a shows the XRD transmission diffractograms of pure CA and BLK wafers. 
Pure CA indicated amorphous structure but the wafer showed crystalline nature due to the 
presence of calcium carbonate (formed from the solvent used to dissolve the polymer) within 
the matrix with sharp peaks at 2θ of 23.06º, 29.42º, 31.53º, 35.97º, 39.42º, 43.16º, 47.53º and 
48.5º. As shown in Fig. 5b pure CIP was highly crystalline in nature, showing several 
characteristic sharp peaks at 14.4º, 20.7º and 25.5º 2θ. Disappearance and / or decrease in 
intensity of these peaks in DL wafers (Fig. 5c) suggests that the drug was molecularly 
dispersed within the polymeric matrix and this is expected to impact upon the rate of drug 
release. Here, it is also important to note that the characteristic peaks of the dressings were 
slightly shifted to higher diffraction angle after loading drug indicating the possible 
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interaction of drug with the polymer. Moreover, the crystallinity of the dressings were 
decreased (data not shown) after loading drug indicating drug-polymer crosslinking and also 
confirmed by FTIR (see supplementary data).   
         
3.5. Fluid (exudate) handling properties 
3.5.1. Porosity 
 The highly porous structure of the wafers was obtained by freeze drying where, the 
gels were initially cooled (freezing) until pure ice crystals form and then sublimed (primary 
drying) from its frozen state under vacuum at low temperature (-25ºC), leaving a highly 
porous microstructure [55]. Their highly porous structure permits transportation of gases, 
nutrients and regulatory factors to allow cell survival, proliferation and differentiation [56]. 
The porosity of BLK and DL dressings was determined by the solvent (ethanol) displacement 
method to avoid hydration of the polymer matrix and collapse of the pores.  
As shown in Table 1 wafers containing more than 0.0001% drug showed a high percentage 
porosity between 98.20 ± 0.56 % to 88.42 ± 4.03%. This could be because the solvent 
penetrated well into the capillaries of wafers due to the roughness of the pore walls as shown 
in SEM images (Fig. 2). The highly porous dressings would play a vital role in carrying 
oxygen into the blood thus preventing ischemia in diabetic foot. All formulations showed the 
higher porosity than Algisite Ag® (71.72 ± 4.17 %).  Therefore, the CIP loaded dressings will 
be expected to absorb more exudates than the commercial product. High porosity also has an 
effect on swelling, Aw, EWC, WVTR and drug release as described below. 
 
3.5.2. Water holding (swelling, Aw and EWC) properties 
The fluid handling ability of wafers plays a vital role in wound healing as it prevents 
maceration of healthy skin tissue in highly exuding DFUs. The swelling capacity of the 
dressings is closely related to porosity as greater number of pores accelerates higher swelling 
ability. However, it also depends on the shape, size and uniformity of the pores in the 
polymeric matrix as well as chemical interaction of polymer and drug with the swelling 
medium [23]. CA and CIP both contain a mixture of hydrophilic and hydrophobic functional 
groups such as hydroxyl, carboxyl, amine and carbonyl groups, which can improve the 
swelling properties. Fig. 6 shows the swelling profiles of BLK and DL wafers in SWF. 
 The initial swelling ability of DL wafers (0.0001-0.005% CIP) was higher compared to BLK 
wafer with values ranging from 2055.30 ± 192.65% to 1476.90 ± 95.69% for the first 15 min. 
After that, the swelling capacities of all DL wafers gradually decreased up to 120 min, and 
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then remained steady for the rest of the study. The initial phase of fluid uptake can be 
explained as follows; the Ca2+ ions present in the mannuronate units of alginate are 
exchanged with Na+ ions in SWF thus allowing faster ingress of fluid into the polymeric 
wafer matrix. Wafers containing more than 0.005% drug exhibited lower swelling capacity 
possibly due to losing their structural integrity resulting in easier polymer erosion in SWF 
during handling and blotting with the tissue paper.  The steady water retention capability of 
the wafers occurred over an extended period thus indicating that the dressings can be used in 
highly exuding DFUs to prevent maceration whilst maintaining a moist wound environment. 
The swelling capacities of formulated wafers were compared with a commercial dressing, 
Algisite Ag (Smith & Nephew, UK). It was observed that the maximum swelling of Algisite 
Ag was about 816.16 ± 28.58% within 15 min (p = 0.0008), which was less than any CIP 
loaded wafers. It could be because the Algisite Ag® fiber mats appeared be less porous (Fig. 
S1) in nature therefore permitted lower rate of water ingress. 
The Aw and EWC capacity are the two important factors affecting the rapid absorption of 
exudates. As shown in Table 1, the BLK wafers exhibited the highest water absorption 
(3373.54 ± 169.85%) and EWC (91.11 ± 0.14%). After drug loading, the Aw and EWC 
gradually decreased with increasing drug content due to the increased cross-linking density of 
CIP with the polymer. Moreover, this could be due to the disturbance in pore size distribution 
as illustrated in SEM images (Fig. 2) after drug incorporation. The irregular pores within 
polymeric microstructure retards water ingress which resulted in decreasing water holding 
capacity into the matrix with increasing drug loading. Wafers containing 0.0001% CIP 
showed maximum water uptake at about 1858.27 ± 65.38 % whilst the Aw of wafers 
containing 0.0005-0.005% CIP were insignificant (p = 0.77) ranging from 1583.21 ± 49.11 to 
1519.85 ± 127.61 %. The water uptake capacities were dramatically decreased after loading 
more than 0.005% drug. This could be attributed to the dense pore network resulting in 
reduced void space to absorb water. The commercial product Algisite Ag® exhibited the 
lowest Aw (580.61 ± 95.30 %) and EWC (85.00 ± 2.21 %) amongst all formulations. This 




Table 1. The Porosity, moisture content, equilibrium water content, water absorption and water vapor transmission rate of different wafer 
formulations and the commercial silver dressing (n = 3 ± SD). 
Sample Porosity (%) Moisture content (%) EWC (%) Water absorption (%) WVTR (g/m2day-1) 
CA-BLK 80.28 ± 1.45 13.28 ± 0.86 97.11 ± 0.14 3373.54 ± 169.85 2577.42 ± 261.98 
CA-CIP 0.0001% 75.81 ± 3.96 16.78 ± 0.39 94.89 ± 0.17 1858.27 ± 65.38 3181.21 ± 48.75 
CA-CIP 0.0005% 88.42 ± 4.03 16.74 ± 0.01 94.05 ± 0.17 1583.21 ± 49.11 3144.91 ± 24.72 
CA-CIP 0.0010% 96.47 ± 2.24 16.71 ± 0.01 93.83 ± 0.14 1521.22 ± 36.77 3111.79 ± 16.79 
CA-CIP 0.0025% 92.03 ± 1.00 16.56 ± 0.08 93.82 ± 0.09 1519.87 ± 23.94 3219.50 ± 59.54 
CA-CIP 0.005% 98.20 ± 0.56 16.79 ± 0.03 93.79 ± 0.51 1519.85 ± 127.61 3445.66 ± 174.36 
CA-CIP 0.010% 95.80 ± 3.06 17.01 ± 0.04 92.74 ± 0.24 1278.46 ± 45.34 3354.37 ± 11.73 
CA-CIP 0.025% 94.79 ± 3.94 17.30 ± 0.04 91.57 ± 0.22 1086.66 ± 31.47 3499.23 ± 71.76 
CA-CIP 0.040% 93.82 ± 2.81 16.83 ± 0.12 89.94 ± 0.78 900.27 ± 74.55 3413.97 ± 98.99 




wafer developed in this study has great potential as an antimicrobial dressing for highly 5 
exuding DFUs.  
 
3.5.3. Water vapor transmission rate 
 WVTR indicates the ability of dressings to absorb fluid and draw it out from the 
wound bed across the materials into the atmosphere. Wound dressings require an adequate 10 
level of moisture transmission to keep the wound area comfortable and promote the healing 
process. Dry wounds exhibit the most water loss thus decrease body temperature and rate of 
metabolism. Therefore, the wound dressing should reduce wound exudate significantly but 
provide adequate moisture content by maintaining a balance between water absorption and 
transmission as well as humidity in the affected wound site [53]. Higher water vapor 15 
transmission rate promotes epithelization process of wound healing whilst lower WVTR 
delays the healing process by accumulating excess wound exudates [57] which leads to skin 
maceration, excoriation and microbial growth.  
 The rate of water loss was linear with time at regular intervals (data not shown). All 
the wafers showed high WVTR (Table 2) that will be expected absorb and transmit exudates 20 
quickly. The high WVTR is attributed to the porosity of the dressings, resulting in the 
increase of voids with capillary adsorbed water. The DL wafers showed greater WVTR 
ranging from 3111.79 – 3499.23 g/m2day-1 compared to the commercial Algisite Ag® 
(2995.97 ± 115.4 g/m2day-1). It has been reported that patients with chronic leg ulcers 
produce 5 g of exudate per 10 cm2/24 h [58], which was equivalent to 5000 g/m2/24 h.  This 25 
suggests that CIP loaded dressings have the potential to absorb and take out about 62-70% 
fluid from chronic wound beds, however, this needs to be confirmed in an in vivo study. 
 
3.5.4. Evaporative water loss 
 The evaporative water loss (EWL) of the wafers was recorded to determine the 30 
behavior of the dressings when exposed to air. As shown in Fig. 7, approximately 20% of 
water loss was observed in CA-BLK and the medicated wafers containing 0.0001-0.025% of 
the drug within 1 h whereas 0.040% DL wafer and Algisite Ag® showed 30% and 40% water 
loss respectively. However, the water loss of CIP loaded wafer increased up to approximately 
87% within 7 h whereas Algisite Ag® had lost this amount within 3 h. After 7 h the loss of 35 
water was insignificant (p = 0.76) and all dressings retained 8-10% of water after 24 h. It 
indicates that the dressings will lose water when exposed to air. Thus, the dressings will be 
21 
 
effective in the early stage of highly exuding wounds such DFUs, as it enables the dressings 
to take up more exudates and edema fluid quickly from the wound bed into its matrix by an 
active upward-directed process [59]. 40 
 
3.5.5. Moisture content 
 Thermogravimetric analysis was used to determine the residual water content of 
wafers after freeze-drying. The moisture content of BLK wafer was about 13.28 ± 0.86 % 
whereas incorporation of CIP into the polymeric wafers resulted in significantly (p = 0.004) 45 
higher moisture content about 16.56 ± 0.08 % to 17.30 ± 0.04 % respectively. This seems to 
indicate that addition of CIP resulted in higher sorption characteristics. However, though, 
high residual water content into wafers is susceptible to microbial growth and also retards 
stability by accelerating crystallization of the drug upon storage [60], the levels are 
comparable to other reported studies [61-63]. Further, high moisture content of the wafers 50 
can maintain the wound and surrounding skin in an optimum state of hydration thus implies 
the dressings to functions efficiently under compression [64]. 
 
3.6. In-vitro drug dissolution and release studies 
 The percentage cumulative release profiles of CIP from the CA based wafers with 55 
different amounts of drug are shown in Fig. 8. Wafers loaded with 0.025% CIP appeared to 
produce the fastest release rate, releasing about 68.36 ± 3.68% of the total drug content 
within 5 min of dissolution. This means the burst release of the dressings can reach MBC for 
killing E. coli, P. aeruginosa and S. aureus within 5 min. However, wafers containing 0.005 
and 0.010% CIP showed total release around 41.89 ± 6.74% and 20.91 ± 6.32% respectively 60 
in 5 min which is also high enough for killing E. coli and P. aeruginosa. The highest 
cumulative percent of CIP released in 6 h was about 59.40 ± 0.64%, 74.39 ± 3.59% and 91.43 
± 1.21% from the wafers loaded with 0.005, 0.010 and 0.025% drug respectively. The 
dressings containing higher amount of CIP appeared to release the drug more rapidly. This 
could be due to disturbance in pore distribution within the wafers. The irregular pore size 65 
allows quick hydration and therefore faster rate of drug release [65]. Though the initial fast 
release is over between 1 and 3 hours, the sustained amounts of CIP from the dressings up to 
6 h can prevent re-infection as well as the need for frequent dressing change.  
 The drug release from wafers was the best fitted (R2= 0.86-0.95) to Korsmeyer-
Peppas mechanism compared to other equations (Table S1) as noted previously [62, 66, 67]. 70 
Therefore, drug released through the polymeric matrix is either by Fickian or non-Fickian 
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diffusion which is the combination of both diffusion and erosion controlled release 
mechanism. Wafers containing 0.005 and 0.025% CIP showed drug release by Fickian 
diffusion as their n values were less than 0.45. The wafer containing 0.010% CIP showed 
non- Fickian diffusion (see details in supplementary section). 75 
 
3.7. In-vitro antimicrobial study 
 In this study, the MIC and MBC (99.9% inhibition) of pure CIP for E. coli, S. aureus 
and P. aeruginosa were recorded as 0.06, 0.5 and 0.125 µg/ml and 0.25, 4, and 0.5 
respectively. On the other hand, the MIC of DL wafers was 0.0001% CIP for E. coli and 80 
0.0005% CIP for S. aureus and P. aeruginosa. Moreover, the wafers with 0.0010 % CIP 
exhibited MBC for E. coli and P. aeruginosa; followed by 0.005% CIP for S. aureus (see 
details in the supplementary section). 
 Antimicrobial activity of CIP loaded wafers and Algisite Ag® were assayed by 
turbidimetric and Kirby-Bauer disk diffusion method. In turbidity assay, optical densities 85 
(OD) of the samples were measured at 625 nm at different time intervals and the turbidity 
was also analyzed visually as shown in Fig. S3 D-F. The clear solutions of bacterial 
suspension confirmed the effectiveness of the released antibiotic in eradicating the bacterial 
load. A significant difference (p= 0.001) in absorbance values was detected between E. coli, 
S. aureus and P. aeruginosa incubated with BLK and antibiotic loaded wafers (Fig. S5 a-c). 90 
BLK wafers did not show any antibacterial effects, which was also confirmed by the ZOI 
assay (Fig. S6). However, the extent of effectiveness of the antibiotic indicated quick release 
of the drug from the polymeric matrix. The OD values of the control and CA-BLK gradually 
increased with time, whereas the values remained below 0.5 in the case of DL wafers during 
the incubation period. The results suggest that the rate of bacterial inhibition was rapid for the 95 
DL dressings and this was further verified by counting number of viable cells at regular time 
intervals during incubation (Fig. S7). Fig. S7 revealed that E. coli (a) and P. aeruginosa (c) 
were completely eradicated within 1.5 h of incubation with the dressings (CA-CIP 0.005%, 





Table 2. Zone of inhibition (ZOI) of CIP loaded wafers and Algisite Ag® against E. coli, S. 
aureus and P. aeruginosa. 






CA-BLK 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
CA-CIP 0.0001% 29.67 ± 0.47 20.00 ± 0.82 31.00 ± 0.82 
CA-CIP 0.0005% 33.83 ± 0.24 25.67 ± 0.47 35.83 ± 0.43 
CA-CIP 0.0010% 34.83 ± 0.65 30.33 ± 0.94 36.83 ± 0.24 
CA-CIP 0.0025% 37.17 ± 0.11 31.67 ± 0.23 37.17 ± 0.39 
CA-CIP 0.005% 40.47 ± 0.41 33.07 ± 0.09 37.40 ± 0.45 
CA-CIP 0.010% 41.43 ± 0.49 33.37 ± 0.29 38.97 ± 0.94 
CA-CIP 0.025% 43.43 ± 0.34 34.67 ± 0.47 40.00 ± 0.08 
CA-CIP 0.040% 45.07 ± 0.40 36.23 ± 0.34 41.33 ± 0.62 
Algiste Ag® 0.00 ± 0.00 33.33 ± 0.49 0.00 ± 0.00 
 
Fig. S6 and Table 2 show the zones and diameter of zone of inhibition (ZOI) 105 
respectively of the tested bacteria in the presence of BLK wafers, DL wafers and Algisite 
Ag®. As shown in Fig. S6 CA-BLK wafer did not show any zone of inhibition against E. coli, 
S. aureus and P. aeruginosa. This result confirmed that the polymer has no antibacterial 
activity alone. However, clear zones of inhibition were observed in DL wafers for both 
Gram-positive and Gram-negative bacteria. In addition, the mean diameters (mm) of ZOI for 110 
all three microorganisms increased with increasing drug content within the wafers. As 
recorded in Table 2 for E. coli the mean diameter of ZOI of the wafers with 0.0001% (MIC) 
and 0.0010% (MBC) CIP was around 29.67 ± 0.47 mm and 34.83 ± 0.65 mm respectively. 
The largest zone (45.07 ± 0.40 mm) was observed against E. coli for the wafer containing 
0.040% CIP. In the case of S. aureus and P. aeruginosa, the ZOI of 0.0005% CIP loaded 115 
wafer (MIC for S. aureus and P. aeruginosa), reached 25.67 ± 0.47 mm and 35.83 ± 0.43 
mm. Moreover, the ZOI for wafers loaded with 0.005% (MBC for S. aureus) and 0.0010% 
(MBC for P. aeruginosa) CIP were recorded around 33.07 ± 0.09 mm and 36.83 ± 0.24 mm 
respectively. Overall higher ZOIs as well as maximum killing ability at low concentration 
confirmed that CIP is more active against E. coli and P. aeruginosa than S. aureus. No 120 
bactericidal activity was detected for Algiste Ag against E. coli and P. aeruginosa except S. 
aureus as illustrated in Fig. S6 with a ZOI value about 33.33 ± 0.49 mm against S. aureus.  
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This implies that CIP loaded wafers have better antimicrobial activity than the commercial 
product. 
     125 
3.8. In-vitro cell viability studies 
 Biocompatibility is a vital requirement recommended by the International 
Organization for Standardization (ISO) for the safe use of medical devices and materials. 
Cytotoxicity test is an integral part of biological evaluation, which determines the prevalence 
of toxic effect and also determines the presence of positive influence in terms of 130 
biofunctionality that promotes wound healing [68]. The biocompatibility of DL dressings was 
evaluated in in vitro cultures of human primary epidermal keratinocytes (PEK) cell line for 
24, 48 and 72h respectively. Keratinocytes are the main cellular component of human skin 
and therefore, selected as an in-vitro model for MTT assay. Moreover, PEK has been 
investigated as a useful model for testing in vitro wound healing activity in the literature 135 
[53,69,70]. The colorimetric MTT assay is based on enzymatic conversion in which MTT is 
converted to purple formazan by the action of dehydrogenase enzymes [71]. In this study, the 
untreated cells and Triton-X-100 (0.01% w/v) treated cells were used as negative (100% 
viable) and positive controls respectively. Algisite Ag was chosen as a representative 
standard commercial sample for the MTT assay. The positive control Triton-X-100 showed 140 
more than 100% cytotoxicity and resulted in a significant reduction in cell viability to values 
below 0% after 72 h treatment. The CIP loaded wafers were found to be highly biocompatible 
with less influence on the viability of the keratinocytes as shown in Fig. 9. Microscopic 
observations (Fig. S8) also revealed the biocompatibility of the dressings to the cells. Wafers 
containing 0.0001-0.025% CIP exhibited more than 85% cell viability whereas 0.040% drug 145 
loaded wafer and Algisite Ag® showed just below 80% cell viability over the 72 h incubation 
period. A time dependent toxicity was also observed after treatment of PEK cells with the 
extracts of CIP loaded wafers. According to the ISO guideline (DIN EN ISO 10993-5) the in 
vitro cell viability of medical devices and materials after exposure should be ≥ 70% to be 
considered as non-cytotoxic [69]. Therefore, according to these guidelines all DL dressings 150 
exhibited acceptable cell viabilities of PEK. Moreover, dressings containing CIP have been 
reported safe to fibroblasts [37]. However, pure CIP has been reported to exhibit time 
dependent cytotoxicity on fibroblast cell lines at concentrations of 0.129 and 0.194 mM, 
following 48 and 72 h of exposure respectively [72]. On the other hand, none of the literature 
reviewed the cytotoxicity of CIP loaded dressings on PEK cell lines. Therefore, the present 155 
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work reveals that CIP loaded lyophilized wafers are non-toxic to PEK and appear to be safe 
dressings for healing of DFUs.    
 
4 Conclusions 
A fluoroquinolone-polymer composite to be applied as a dressing in DFUs was formulated 160 
and characterised in terms of functional physicochemical properties, antimicrobial activity 
and cell viability. The uniform distribution of CIP within the CA based polymeric matrix was 
confirmed by SEM, FTIR and XRD. The evaluation of swelling, porosity, moisture content, 
water absorption and EWC showed high capacity of handling wound exudates which can 
prevent maceration of healthy skin cells in DFU. In addition, WVTR (3111.79 – 3499.23 165 
g/m2day-1) and EWL (87% within 7 h) study reflected optimal conditions for maintaining 
moist environment, which is necessary for wound healing. The rapid eradication of three 
common infection causative bacteria; E. coli, S. aureus and P. aeruginosa was attributed to 
initial burst release of drug.  The lyophilized wafers showed acceptable cell viability above 
70% with respect to ISO standard. By considering the data of antimicrobial and cell viability 170 
studies, it will be a potential dressing for patients with DFUs infected with drug resistant 
bacteria. In addition, the CIP loaded wafers showed better fluid handling capacity, bacterial 
inhibition as well as cell survival (MTT assay) than Algisite Ag® commercial dressing. 
Therefore, the CIP loaded wafers will be potentially a better dressing than the commercial 
product for DFUs.  Studies of cell migration and attachment as well as in vivo animal testing 175 
are needed to elucidate the wound healing action of the lyophilized dressings. 
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Figure 1 Digital images of CA wafers prepared from gels of different concentrations based on 390 
total polymer weight 
 
Figure 2 SEM images of BLK and CIP loaded wafers captured at x200 magnification 
 
Figure 3 Hardness profiles of formulated wafers (n = 3) prepared from 1% w/w gels, 395 
compressed at three different places on both sides of the dressing showing effect of drug 
loading 
 
Figure 4 Adhesive profiles of CIP loaded wafers in the presence of (a) thin SWF containing 
2% (w/w) BSA and (b) viscous SWF containing 5% (w/w) BSA 400 
 
Figure 5 XRD patterns of (a) pure polymer and BLK wafer, (b) pure drug and (c) drug loaded 
wafers 
 
Figure 6 Swelling behavior of the different CA based dressings tested 405 
 
Figure 7 Evaporative water loss from Algisite Ag®, BLK and DL wafers 
 
Figure 8 Cumulative percentage drug release profiles of optimized CIP loaded wafers  
 410 
Figure 9 Cell viability of human primary epidermal keratinocytes after expositions to the 
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Figure 3 Hardness profiles of formulated wafers (n = 3) prepared from 1% w/w gels, 
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